Gold Prices Prep fo...
Health Care: Drugs
Orexigen Therapeutics Inc. (OREX: NASDAQ)
$3.17 0.05 | 1.60%
02/08/12 - 04:00 PM ET
553.02K / 533.30K
Vol / Avg. Vol:3.07 / 3.12
Open / Prev. Close:3.03 - 3.19
Today's Range:1.22 - 4.10
52 Wk Range:96.89%
Performance YTD:TheStreet Rating:
Portfolios with OREX
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- Contributor5 Stocks Under-$10 Setting ...
- UserBlind Rookie
- UserPRossmango - Speculative Lo...
- UserPersonal selections
- Contributor$5 Stocks That Analysts Exp...
- ContributorFast Money's Personal Healt...
- UserSUPRATRADE Top 10 Best-Rate...
- UserPART 5 JPMorgan 28th Annual...
- Userchairmaker Portfolio 1
Latest OREX Headlines from TheStreet
- 6 Stocks Under $10 Moving Higher 01.22.12 | 01:01 pm
- Vivus Identifies Birth Defect Risk Tied to Weight-Loss Drug Qnexa 12.22.11 | 07:12 am
- Biotech Stock Mailbag: 2011 Report Card 11.25.11 | 05:11 am
- General Mills, BofA, Oracle Are Market Movers 09.21.11 | 04:09 pm
- 12 Stocks to Watch: Orexigen, Walter Energy 09.21.11 | 08:09 am
- Orexigen: Contrave's Odds Still Slim 09.21.11 | 08:09 am
- Adobe, Orexigen: After-Hours Trading 09.20.11 | 06:09 pm
- Orexigen Resurrects Rejected Obesity Drug 09.20.11 | 04:09 pm
- Biotech Stock Mailbag: Sangamo Biosciences 07.22.11 | 05:07 am
- Orexigen Stock Hits New 52-Week Low (OREX) 06.17.11 | 01:06 pm
Press Releases for OREX
- Orexigen® Therapeutics Completes Public Offering Of Common Stock And Warrants To Purchase Common Stock - PR Newswire 12.22.11 | 04:12 pm
- Orexigen Therapeutics To Present At The Lazard Capital Markets Healthcare Conference - PR Newswire 11.11.11 | 08:11 am
- Orexigen® Therapeutics Presents Multiple Contrave® Data Presentations At The 29th Annual Scientific Meeting Of The Obesity Society - PR Newswire 10.03.11 | 08:10 am
- Orexigen Therapeutics To Present At The JMP Securities Healthcare Conference - PR Newswire 09.26.11 | 08:09 am
- Orexigen And FDA Identify A Clear And Feasible Path To Approval For Contrave® - PR Newswire 09.20.11 | 04:09 pm
- Orexigen® Therapeutics Provides A Regulatory Update On Contrave® NDA - PR Newswire 06.03.11 | 07:06 am
- Orexigen® Therapeutics Schedules June 3, 2011 Webcast And Conference Call To Provide A Regulatory Update On Contrave® NDA - PR Newswire 06.01.11 | 08:06 am
- Orexigen® Therapeutics Schedules May 9, 2011 Webcast Discussion Of Financial Results For The First Quarter Ended March 31, 2011 - PR Newswire 05.02.11 | 08:05 am
- Orexigen® Therapeutics Presents Additional Contrave® Data From Phase 3 COR-II Trial On 24-Hour Ambulatory Blood Pressure Monitoring - PR Newswire 04.04.11 | 08:04 am
- Orexigen® Therapeutics Reports Fourth Quarter And Year Ended December 31, 2010 Financial Results - PR Newswire 03.10.11 | 04:03 pm
Partner Headlines for OREX
- Zacks #1 Rank Additions for Thursday - Tale of the Tape - Zacks 12.08.11 | 09:12 am
- Will These 4 Biotech Stocks Make You Rich? - Seeking Alpha 10.11.11 | 09:10 am
- Emisphere: Crown Jewel In Oral B12 - Seeking Alpha 10.07.11 | 09:10 am
- Lifeline for Orexigen's Contrave - Analyst Blog - Zacks 09.22.11 | 06:09 pm
- Company News for September 22, 2011 - Corporate Summary - Zacks 09.22.11 | 10:09 am
- Morning Market Movers - Benzinga 09.21.11 | 09:09 am
- UPDATE 3-Orexigen slates diet-pill trial, shares jump - Reuters 09.20.11 | 05:09 pm
- UPDATE 2-US FDA rebuffs Orexigen proposals on obesity drug - Reuters 06.03.11 | 08:06 am
- Company News for June 02, 2011 - Corporate Summary - Zacks 06.02.11 | 10:06 am
- Morning Market Movers - Benzinga 06.01.11 | 09:06 am
